Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials.
Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, Honig LS, Cassetta E, Woodward M, Boada M, van Dyck CH, Grimmer T, Selkoe DJ, Schneider A, Blondeau K, Hu N, Quartino A, Clayton D, Dolton M, Dang Y, Ostaszewski B, Sanabria-Bohórquez SM, Rabbia M, Toth B, Eichenlaub U, Smith J, Honigberg LA, Doody RS. Ostrowitzki S, et al. Among authors: quartino a. JAMA Neurol. 2022 Nov 1;79(11):1113-1121. doi: 10.1001/jamaneurol.2022.2909. JAMA Neurol. 2022. PMID: 36121669 Free PMC article. Clinical Trial.
ABBY: A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease.
Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Rabe C, Brunstein F, Quartino A, Honigberg LA, Fuji RN, Clayton D, Mortensen D, Ho C, Paul R. Cummings JL, et al. Among authors: quartino a. Neurology. 2018 May 22;90(21):e1889-e1897. doi: 10.1212/WNL.0000000000005550. Epub 2018 Apr 25. Neurology. 2018. PMID: 29695589 Free PMC article. Clinical Trial.
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
Salloway S, Honigberg LA, Cho W, Ward M, Friesenhahn M, Brunstein F, Quartino A, Clayton D, Mortensen D, Bittner T, Ho C, Rabe C, Schauer SP, Wildsmith KR, Fuji RN, Suliman S, Reiman EM, Chen K, Paul R. Salloway S, et al. Among authors: quartino a. Alzheimers Res Ther. 2018 Sep 19;10(1):96. doi: 10.1186/s13195-018-0424-5. Alzheimers Res Ther. 2018. PMID: 30231896 Free PMC article. Clinical Trial.
Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks.
Guthrie H, Honig LS, Lin H, Sink KM, Blondeau K, Quartino A, Dolton M, Carrasco-Triguero M, Lian Q, Bittner T, Clayton D, Smith J, Ostrowitzki S. Guthrie H, et al. Among authors: quartino a. J Alzheimers Dis. 2020;76(3):967-979. doi: 10.3233/JAD-200134. J Alzheimers Dis. 2020. PMID: 32568196 Free PMC article. Clinical Trial.
Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires.
Svensson RJ, Ribbing J, Kotani N, Dolton M, Vadhavkar S, Cheung D, Staton T, Choy DF, Putnam W, Jin J, Budha N, Karlsson MO, Quartino A, Zhu R. Svensson RJ, et al. Among authors: quartino a. CPT Pharmacometrics Syst Pharmacol. 2021 Oct;10(10):1221-1235. doi: 10.1002/psp4.12690. Epub 2021 Aug 5. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34346168 Free PMC article. Clinical Trial.
Safety, Tolerability, and Pharmacokinetics of High-Volume Subcutaneous Crenezumab, With and Without Recombinant Human Hyaluronidase in Healthy Volunteers.
Dolton MJ, Chesterman A, Moein A, Sink KM, Waitz A, Blondeau K, Kerchner GA, Hu N, Brooks L, Wetzel-Smith MK, Roden A, Deshmukh A, Peng K, Carrasco-Triguero M, Smith J, Ostrowitzki S, Quartino A. Dolton MJ, et al. Among authors: quartino a. Clin Pharmacol Ther. 2021 Nov;110(5):1337-1348. doi: 10.1002/cpt.2385. Epub 2021 Aug 27. Clin Pharmacol Ther. 2021. PMID: 34347883 Clinical Trial.
Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates.
Ramakrishnan V, Friedrich C, Witt C, Sheehan R, Pryor M, Atwal JK, Wildsmith K, Kudrycki K, Lee SH, Mazer N, Hofmann C, Fuji RN, Jin JY, Ramanujan S, Dolton M, Quartino A. Ramakrishnan V, et al. Among authors: quartino a. CPT Pharmacometrics Syst Pharmacol. 2023 Jan;12(1):62-73. doi: 10.1002/psp4.12876. Epub 2022 Nov 6. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36281062 Free PMC article.
46 results